TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.0100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.0800nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.0900nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.100nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.140nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.157nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.162nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.200nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.240nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.300nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.400nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 0.600nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 1nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 4nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: 5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein phosphatase beta(Homo sapiens (Human))
Aerpio Therapeutics
US Patent
Aerpio Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HPTP-β inhibition can be tested by any method chosen by the formulator, for example, Amarasinge K. K. et al., “Design and Synthesis of Potent, N...More data for this Ligand-Target Pair